Introduction & Objective: Electronic health records (EHR) are a valuable source of real-world data for clinical research. Reliable methods are needed to identify type 1 diabetes (T1D) by EHR. The study aim was to develop an EHR algorithm for T1D using diagnosis codes and clinical characteristics validated by manual chart review.

Methods: Data from the Center for Kidney Disease Research, Education, and Hope (CURE-CKD) Registry were used to identify persons ≥12 years of age with T1D by diagnosis codes, ketoacidosis encounters, insulin pump and short-acting insulin use during 2013-2022. Manual chart review was performed on a subset of 100 participants to verify selection criteria; 40 from “very likely” category, 40 from “likely” category, and 20 from “unlikely”.

Results: T1D cohorts (N=31,695) were divided into likelihood categories based on confirming criteria (Figure). The cohort was 48.5% female and 75.7% White race identity. Their mean±SD for age was 42±19 years with HbA1c 8.2±2.1% and BMI 27.5±6.3 kg/m2. Positive predictive values were 100% for very likely, 98% for likely, and 40% for unlikely categories.

Conclusions: T1D can be reliably identified by the CURE-CKD algorithm using clinical EHR data. Pending further validation, this algorithm can be used for T1D cohort selection in real-world studies of epidemiology, diagnosis, and treatment.

Disclosure

C. Greenbaum: Other Relationship; Sanofi, Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Imcyse. C.L. Reynolds: None. C. Jones: None. L. Kornowske: None. K.B. Daratha: None. R.Z. Alicic: Advisory Panel; Bayer Inc., Boehringer-Ingelheim. Research Support; AstraZeneca, Bayer Inc., AstraZeneca, Novo Nordisk, Traveere Pharmaceuticals. J.J. Neumiller: Advisory Panel; Bayer Inc., Boehringer-Ingelheim, Eli Lilly and Company, Proteomics International. K.R. Tuttle: Consultant; Lilly Diabetes. Research Support; Boehringer-Ingelheim. Consultant; AstraZeneca. Research Support; Novo Nordisk, Bayer Inc., Traveere Pharmaceuticals. Consultant; Pfizer Inc.

Funding

CDC (75D301-21-P-12254)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.